摘要
目的探讨参附注射液对择期经皮冠状动脉介入治疗(PCI)术后病人炎症因子、纤溶活性及冠状动脉血流的影响。方法将112例冠心病病人随机分为常规治疗组(54例)和参附治疗组(58例),选取50名健康体检者为健康对照组。两组病人均于PCI术前给予常规治疗,参附治疗组加用参附注射液60 mL静脉输注,每日1次,疗程为10 d。各组分别于治疗前及PCI术后测定血中超敏C-反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、纤维蛋白原(Fib)、纤溶酶原激活物抑制剂1(PAI-1)活性、D-二聚体(DD)、肌酸激酶同工酶(CK-MB)水平。结果与健康对照组比较,常规治疗组和参附治疗组hs-CRP、IL-6、PAI-1明显增高(P <0.05或P <0.01)。与治疗前比较,参附治疗组PCI术后IL-6、Fib、PAI-1、DD均降低(P <0.05或P <0.01),CK-MB升高(P <0.05),而常规治疗组hs-CRP、IL-6、PAI-1、DD、CK-MB均明显升高(P <0.05或P <0.01)。与常规治疗组治疗后比较,参附治疗组hs-CRP、IL-6、PA-1、DD、CK-MB水平均明显降低,心肌梗死溶栓试验(TIMI)冠状动脉血流分级<3级的比例明显降低(P <0.01)。结论参附注射液可以减少PCI术后炎症反应,提高纤溶活性,降低心肌缺血再灌注损伤,可作为PCI围术期心肌保护的治疗措施。
Objective To explore the effects of Shenfu injection （SFI） on the inflammatory factors, fibrinolytic activity,and myocardialreperfusion in patients undergoing elective percutaneous coronary intervention （PCI）.Methods One hundred and twelve patients withcoronary heart disease （CHD） were randomly divided into two groups： routine treatment group （ n =54） treated with routine treatment,and SFI group （ n =58） treated with SFI plus routine treatment for 10 days.Fifty healthy individuals were as health control group.Highsensitivity C reactive protein （hs CRP）,interleukin 6 （IL 6）,fibrinogen （Fib）,plasminogen activator inhibitor 1 （PA 1）,D dimer（DD） and creatine kinase isoenzyme （CK MB） levels were measured before and after PCI.Results Compared with healthy controls,the levels of hs CRP,IL 6,and PAI 1 were significantly higher in routine treatment group and SFI group （ P 〈0.05 or P 〈0.01）.Compared with that before treatment,IL 6,Fib,PAI 1,and DD were decreased after PCI in SFI group （P 〈0.05 or P 〈0.01）,and CK MB,was increased （P 〈0.05）,while hs CRP,IL 6,PAI 1,DD,and CK MB were significantly increased in routine treatment group （P 〈0.05 or P 〈0.01）.Compared with routine treatment group after treatment, the levels of Hs CRP, IL 6,PAI 1,DD,CK MB and the〈proportion of thrombolysis in myocardial infarction trial （TIMI） flow 〈3 were significantly decreased in SFI group （ P 〈0.01）.Conclu -sion SFI can reduce the postoperative inflammatory response,improve fibrinolytic activity,and reduce myocardial ischemia reperfu -sion injury in patients with CHD.It can be used as a treatment for myocardial protection during perioperative period of PCI.
作者
渠莉
袁涛
傅蓉
Qu Li;Yuan Tao;Fu Rong(The Eighth People ′ s Hospital of Qingdao,Qingdao 266100,Shandong,China)
出处
《中西医结合心脑血管病杂志》
2018年第17期2533-2536,共4页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词
冠心病
经皮冠状动脉介入治疗
参附注射液
炎症因子
纤溶指标
心肌灌注
coronary heart disease
percutaneous coronary intervention
Shenfu injection
inflammatory factors
fibrinolytic activity
myo -cardial reperfusion
